Revance therapeutics to release second quarter 2016 financial results thursday, august 4, 2016

Newark, calif.--(business wire)--revance therapeutics, inc. (nasdaq:rvnc), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release second quarter 2016 financial results on thursday, august 4, 2016 after the close of market. revance will host a corresponding conference call and a live webcast at 1:30pm pt/4:30pm et on the same day to discuss the results and provide a business and pipeline update. individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference id: 46636498; or from the webcast link in the investor relations section of the company's website at: www.revance.com. a replay of the call will be available beginning august 4, 2016 at 5:00pm pt/8:00pm et to august 5, 2016 at 5:00pm pt/8:00pm et. to access the replay, dial (855) 859-2056 or (404) 537-3406 and reference conference id: 46636498. the webcast will be available in the investor relations section on the company's website for 30 days following the completion of the call. about revance therapeutics, inc. revance, a silicon valley-based biotechnology company, is committed to the advancement of remarkable science. the company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. revance's trajectory to commercial success begins with the company's novel and proprietary transmts® carrier-peptide delivery system applied to botulinum toxin. revance is developing daxibotulinumtoxina, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. the company holds worldwide rights for all indications of daxibotulinumtoxina topical gel (rt001), daxibotulinumtoxina for injection (rt002) and the transmts technology platform. beyond botulinum toxin, revance believes the transmts technology can be applied to transdermal, mid-dermal, or deep tissue delivery of a variety of other macromolecules. more information on revance can be found at www.revance.com. "revance therapeutics", transmts®, “remarkable science changes everything”, and the revance logo are registered trademarks of revance therapeutics, inc.
RVNC Ratings Summary
RVNC Quant Ranking